Genfit Dives Into Uncertain Late-stage NASH Trial
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Genfit Pivots To Opposite End Of The Liver Disease Spectrum
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
Stockwatch: Intercepting The Falling Knives Of NASH
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
RESOLVE-IT Failure Dashes Genfit's NASH Hopes
Genfit SA is now pinning its hopes for elafibranor on primary biliary cholangitis after the dual PPAR alpha/delta agonist failed in its Phase III RESOLVE-IT trial for NASH.